

REC Ref No.	IRAS No.	Name of Trial	Target Number of Participants Available?	Recruitment Target	Target Date To Recruit Participants Available?	Date Agreed To Recruit Target Number of Participants	Total Number of Participants Recruited at The Agreed Target Date	Date Study Closed to Recruitment	Recruitment Total	RTT Met?	Recruitment Closure Reason
20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734TM) Treatment of COVID-19 in an Outpatient Setting	Number Agreed	12	Date Agreed	30/06/2021			0	No	Recruitment Finished
20/EE/0204	287569	A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMERâ€™S DISEASE	Number Agreed	6	Date Agreed	12/03/2021			6	Yes	Recruitment Finished
20/YH/0171	284062	An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 WHO grade 3&4 (NOCov2)	Number Agreed	10	Date Agreed	31/12/2020			14	Yes	Recruitment Finished
19LO1183	269900	IPX203-B16-03	Number Agreed	1	Date Agreed	31/12/2021	0	31/03/2021	0	No	Recruitment Finished
20/YH/0090	278137	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMERâ€™S DISEASE	Number Agreed	2	Date Agreed	07/09/2020	2	30/09/2020	2	Yes	Recruitment Finished
18/EM/0323	251531	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Number Agreed	1	Date Agreed	23/04/2021			0	No	Withdrawn By Sponsor
18/WS/0218	252602	An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)	Range Agreed	1	Date Agreed	30/06/2021			0	No	Recruitment Finished
19/LO/1583	271866	A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sick Cell Disease	Number Agreed	5	Date Agreed	03/06/2021			1	No	Recruitment Finished
18/WS/0187	242800	Retrospective and prospective international EKOsoNicÂ® registry Of the treatment and Clinical OUTcomes of patients with Pulmonary Embolism	Number Agreed	3	Date Agreed	31/03/2020	1	30/09/2020	1	No	Recruitment Finished
19/SC/0422	268966	An Open-Label, Long-Term Safety Evaluation Study with DCCR	Number Agreed	3	Date Agreed	15/03/2021			1	No	Recruitment Finished
19/LO/1263	263485	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Number Agreed	1	Date Agreed	01/12/2020	1	01/12/2020	1	Yes	Recruitment Finished
19/NW/0328	263312	A Phase 2 Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis	Number Agreed	2	Date Agreed	31/12/2020	0	15/03/2021	0	No	Recruitment Finished

18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	2	Date Agreed	31/03/2021	1		3	Yes	Recruitment Finished
19/NW/0174	261666	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers	Number Agreed	3	Date Agreed	31/12/2020	6	30/10/2020	6	Yes	Recruitment Finished
19/WS/0015	257933	A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease	Number Agreed	5	Date Agreed	31/03/2021			0	No	Recruitment Finished
19/NE/0022	254999	A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Doubleblind, Placebo-controlled Clinical Trial	Range Agreed	3	Date Agreed	30/06/2021			1	No	Recruitment Finished
19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	Number Agreed	1	Date Agreed	30/06/2021	1	15/04/2021	1	Yes	Recruitment Finished
19/EM/0020	252705	A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAPER)	Number Agreed	2	Date Agreed	30/11/2020	3		3	Yes	Recruitment Finished
19/LO/0150	258058	A double-blind, placebo-controlled, randomised phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut-allergic young children 1-3 years of age	Number Agreed	10	Date Agreed	31/07/2020	7	31/07/2020	7	No	Recruitment Finished
19/NW/0342	264974	A Phase 3/4, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)	Number Agreed	2	Date Agreed	20/12/2020			0	No	Recruitment Finished
18/EE/0099	239606	An open label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)	Number Agreed	10	Date Agreed	31/03/2020	2	19/08/2020	2	No	Recruitment Finished
19/YH/0013	255993	A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who have not received Previous Systemic Anticancer therapy.	Number Agreed	3	Date Agreed	04/01/2023	3	19/08/2020	3	Yes	Recruitment Finished
19/LO/1183	259840	IPX203-B16-02	Number Agreed	3	Date Agreed	30/07/2020	1	30/07/2020	3	Yes	Recruitment Finished
18/SC/0591	250421	A Randomized, Open Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor of High Tumor Mutational Burden (TMB-H)	Number Agreed	3	Date Agreed	21/01/2021		15/01/2021	3	Yes	Recruitment Finished

18/LO/1258	248312	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis	Number Agreed	2	Date Agreed	30/09/2020	1	31/12/2020	1	No	Withdrawn By Sponsor
19/SC/0350	266934	A Phase 1B, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Inhaled GB002, and Assess Changes in Imaging and Biomarkers in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH)	Number Agreed	2	Date Agreed	31/10/2020	1	31/12/2020	1	Yes	Recruitment Finished
17/LO/0232	220795	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations	Number Agreed	4	Date Agreed	31/03/2021	1	17/03/2021	2	No	Withdrawn By Sponsor
18/SC/0240	230920	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease	Number Agreed	8	Date Agreed	11/01/2021			9	Yes	Recruitment Finished
18/WA/0276	246112	Randomised Double-Blind, Placebo-Controlled (within dose groups) and Active Controlled (Eplerenone group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients with Diabetic Nephropathy	Number Agreed	2	Date Agreed	30/10/2020	0	29/07/2020	0	No	Recruitment Finished
18/NW/0765	250220	Validating a Device for the Detection of Bacteria and Leukocytes in Peritoneal Effluent from Patients with Suspected Peritonitis	Number Agreed	10	Date Agreed	02/11/2020	13	31/12/2020	13	Yes	Recruitment Finished
17/WM/0117	223480	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	Number Agreed	3	Date Agreed	31/01/2021			3	Yes	Recruitment Finished
18/LO/1215	245798	A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 "TRIAL of erYaspase in pancreatic CAncer	Range Agreed	2	Date Agreed	08/02/2021	2	01/12/2020	2	Yes	Recruitment Finished
18/LO/1882	253030	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer	Number Agreed	2	Date Agreed	16/11/2020	2	23/10/2020	2	Yes	Recruitment Finished
18/NE/0214	245998	MN39158 - A Long Term Extension Study in Multiple Sclerosis	Number Agreed	3	Date Agreed	01/06/2020	3		3	Yes	Recruitment Finished
18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Number Agreed	35	Date Agreed	23/10/2020			35	Yes	Recruitment Finished
18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Dose Finding, Placebo Controlled, Safety, Efficacy and Pharmacokinetic Study of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	Range Agreed	2	Date Agreed	31/08/2020	1	02/07/2020	1	No	Withdrawn By Sponsor
18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Number Agreed	2	Date Agreed	06/05/2021			2	Yes	Recruitment Finished

18/NE/0136	240494	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	Number Agreed	1	Date Agreed	18/12/2020	0	18/12/2020	0	No	Recruitment Finished
18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	Number Agreed	32	Date Agreed	13/06/2022			32	Yes	Recruitment Finished
17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebocontrolled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	Number Agreed	2	Date Agreed	30/07/2020	0	30/07/2020	0	No	Recruitment Finished
18/WM/0022	237623	AG-348 in Regularly Transfused Adult Subjects with PK Deficiency	Range Agreed	1	Date Agreed	27/09/2020	1	27/09/2020	1	Yes	Recruitment Finished
17/WS/0180	225790	A Phase 111b, Randomised, Double-blind, Placebocontrolled, MulticentreStudy of Olaparib Maintenance Retreatment in Patients with EpithelialOvarian Cancer Previously Treated With a PARPi and Responding toRepeat Platinum Chemotherapy (OReO)	Number Agreed	4	Date Agreed	30/04/2021	1	15/01/2021	2	No	Recruitment Finished
17/LO/1590	229278	A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585).	Number Agreed	4	Date Agreed	01/03/2021	4	31/12/2020	5	Yes	Recruitment Finished
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimerâ€™s Disease	Number Agreed	4	Date Agreed	30/06/2020	4		4	Yes	Recruitment Finished
16/EE/0421	209972	A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension	Number Agreed	2	Date Agreed	31/12/2020			0	No	Recruitment Finished